Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guci Shangtong patch is a Traditional Chinese Medicine (TCM) topical preparation developed by Hangzhou Tiancheng Pharmaceutical Co., Ltd. for the treatment of pain associated with lumbar spondylosis and lumbar osteoarthritis. The formulation is specifically designed for patients presenting with the TCM syndrome of meridian stasis and liver-kidney deficiency. As a transdermal patch, it delivers herbal active ingredients directly to the affected area to improve local blood circulation, alleviate pain, and reduce inflammation. The drug has been evaluated in multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trials in China to assess its efficacy and safety in managing degenerative spinal conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guci Shangtong patch.